TLR9 and B-cell chronic lymphocytic leukemia: In addition, in primary CLL cells (n = 12 IGHV-U patients) with and without TLR9 stimulation using synthetic CpG oligodeoxynucleotide, 72 h PRT382 treatment resulted in a dose-dependent reduction in proliferative potential in vitro (Supplemental Fig. 6B).